The American journal of gastroenterology
-
Am. J. Gastroenterol. · May 2020
Randomized Controlled Trial Multicenter StudyMongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
The objective was to assess the efficacy and safety of GED-0301, an antisense oligodeoxynucleotide to Smad7, in active Crohn's disease (CD). ⋯ GED-0301 did not demonstrate efficacy vs placebo in active CD.